Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had better overall survival at Kidney Cancer Association 2017 in Miami.
Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had better overall survival
